Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition
AssigneePurdue Research Foundation
InventorsXiaoping Bao, Yun Chang
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to a method for producing hematopoietic stem cells and progenitor cells for therapeutic uses through a two-step process manipulating the canonical Wnt signaling pathway. Started from human pluripotent stem cells, the activation of the canonical Wnt signaling pathway of those stem cells is followed by downregulation of the Wnt signaling via various methods, including TGF-beta inhibition. Pharmaceutical composition matters and methods for treating a patient of hematopoietic diseases by administering therapeutically effective amounts of said stem cells or progenitor cells alone or together with other therapeutics are within the scope of this disclosure.
Claims19
A method for generating hematopoietic stem cells (HSCs) and progenitor cells from human pluripotent stem cells (hPSCs) comprising the steps of:
- a. preparing human pluripotent stem cells (hPSCs);
- b. preparing a culture medium comprising a glycogen synthase kinase-3 (GSK3) inhibitor, wherein said GSK3 inhibitor is to activate the canonical Wnt signaling pathway of said hPSCs;
- c. culturing the undifferentiated hPSCs in the culture medium containing the GSK3 inhibitor to activate the canonical Wnt signaling pathway in the undifferentiated hPSCs and initiate differentiation in the undifferentiated hPSCs;
- and
- d. then downregulating the activated canonical Wnt signaling pathway or transforming growth factor beta (TGF-beta) signaling pathway for a period of time to induce and generate said hematopoietic stem cells (HSCs).
Dependencies are inferred from the claim text.